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Diabetic retinopathy (DR) is a most severe microvascular complication which, if left unchecked, can be sight-threatening. With
the global prevalence of diabetes being relentlessly projected to rise to 438 million subjects by 2030, DR will undoubtedly pose
a major public health concern. Eﬀorts to unravel the human genetics of DR have been undertaken using the candidate gene and
linkage approaches, while GWAS eﬀorts are still lacking. Aside from evidence for a few genes including aldose reductase and
vascular endothelial growth factor, the genetics of DR remain poorly elucidated. Nevertheless, the promise of impactful scientiﬁc
discoveries may be realized if concerted and collaborative eﬀorts are mounted to identify the genes for DR. Harnessing new genetic
technologies and resources such as the upcoming 1000 Genomes Project will help advance this ﬁeld of research, and potentially
lead to a rich harvest of insights into the biological mechanisms underlying this debilitating complication.
1.Introduction
Diabetic retinopathy (DR) is a most severe microvascu-
lar complication which if left unchecked can be sight-
threatening. DR ranks as a common cause of blindness
worldwide, particularly among adults [1–3]. With the global
prevalence of diabetes being projected to rise to 438 million
subjectsby2030,DRwillcertainlyposeamajorpublichealth
concern [4].
The presence of diabetic retinopathy is evidenced by the
appearance of retinal microvascular lesions. Early changes
include microaneurysms, hemorrhages, hard exudates, cot-
tonwoolspots,intraretinalmicrovascularabnormalities,and
venous beading and characterize nonproliferative diabetic
retinopathy (NPDR). The more severe state of proliferative
diabetic retinopathy (PDR) is marked by the formation
of abnormal fragile new blood vessels that are prone
to hemorrhage. Finally, visual impairment results in sec-
ondary to pre-retinal or vitreous hemorrhage and diabetic
maculopathy.
2. FamilialClusteringof DR
Epidemiological studies have shown that the prevalence of
DR increases with diabetes duration and various clinical
measures, primarily intensive glycaemic control, can delay
the development of DR [5, 6]. It is however noteworthy that
somepatientsmaystilldevelopDRevenwithgoodglycaemic
control. Conversely, some patients with poor glycaemic
control are spared from this complication and notably, in
long surviving patients with type 1 diabetes, the association
between diabetic retinopathy and glycaemic control is less
well supported [7]. Genetic susceptibility may underlie this
observation, a proposal that was supported by twin analysis
conducted more than three decades ago [8]. Of late, this
e a r l ye v i d e n c ef o rar o l eo fg e n e t i cf a c t o r si nD Rh a sb e e n
corroborated by familial aggregation studies among patients
with either type 1 or type 2 diabetes (Table 1). Familial
clustering also extends across diﬀerent ethnicities. This eﬀect
of genes likely inﬂuences the various stages of DR including
NPDR, PDR, and macular edema although diﬀerent genes
may impact speciﬁc stages of disease [9–13].2 Journal of Ophthalmology
3. CandidateGenes for DR
The search for DR genes has predominantly been under-
taken using the candidate gene approach. The case-control
study design is generally employed and is appropriate for
detecting both major and minor genes. The candidate
gene approach requires a fair knowledge of the pathogenic
mechanisms underlying DR and this has beneﬁtted from
the many years of research in this ﬁeld [14–16]. Several
pathways and processes have been strongly implicated
including the renin-angiotensin system, polyol pathway,
nonenzymatic glycation, endothelial dysfunction, vascular
tone maintenance, extracellular matrix remodeling, and
angiogenesis which is dysregulated in diabetes leading to
proliferation of new fragile retinal capillaries that culmi-
nate in PDR [17, 18]. Correspondingly, a host of genes
involved in these pathways/processes have been treated as
potential candidate genes. These genes include angiotensin-
I converting enzyme (ACE), angiotensin II type 1 recep-
tor (AGTR1), angiotensinogen (AGT), vascular endothelial
growth factor (VEGF), aldose reductase (AR2), receptor
for advanced glycation endproducts (RAGE), glucose trans-
p o r t e r1( GLUT1), inducible and constitutive nitric oxide
synthases (NOS2A, NOS3), transforming growth factor beta
(TGFbeta), endothelin isoforms, and its cellular receptors,
among others [19–28].
As is the current thought in the ﬁeld of complex genetics,
the eﬀect sizes of these genetic factors are likely to be
modest although major genes have been postulated to exist.
Consequently, individual studies have, more often than not,
yielded inconsistent and even conﬂicting ﬁndings [29]. To
circumventthisissue,meta-analyseshavebeenundertakento
pinpoint the few genes for which there might be cumulative
evidence for an association with DR. Three of these genes are
highlighted in the following sections.
4. Aldose Reductase(AKR1B1, Human
Chromosome 7q35)
Aldose reductase (AKR1B1) is the rate-limiting enzyme
of the polyol pathway, which catalyzes NADPH-dependent
reduction of glucose to sorbitol. AKR1B1 has been reported
in human pericytes, and activation of this pathway has been
strongly implicated in the pathogenesis of DR. Notably,
retinal vascular changes such as microaneurysm formation
and degeneration of retinal pericytes may be induced in rats
and dogs that have been made hyperglycemic by a diet rich
in galactose, the latter being reduced by AKR1B1 to form
galactitol [14, 15]. The search for pharmacological inhibitors
ofthisenzymeforuseinthetreatmentofDRisongoing[30].
In a recent meta-analysis of the various polymorphisms in
AKR1B1, the Z-2 allele of the (CA)n microsatellite located at
the5  endofthegeneshowedthemostsigniﬁcantassociation
with diabetic retinopathy (OR = 2.33, 95% CI = 1.49–3.64,
P = .0002), independently of the type of diabetes present.
This association was present regardless of whether cases had
NPDR (OR = 1.64, 95% CI = 1.14–2.35, P = .0075) or PDR
(OR=1.51,95%CI=1.16–1.97,P = .0023)[31].Conversely,
the Z + 2 and Z alleles conferred protection against DR
[31]. Beside the (CA)n microsatellite, the association of the
promoter SNP rs759853 and DR has also been reported in a
number of studies. Meta-analysis suggested that the T allele
conferred protection against DR in type 1 diabetes (OR =
0.49, 95% CI 0.36–0.68, P<. 0001) while there was no
statistically signiﬁcant association in patients with type 2
diabetes [31].
5.VascularEndothelialGrowthFactor
(VEGF, HumanChromosome 6p12)
VEGF is an important growth factor involved in causing
vascular permeability. High vitreous levels have been repeat-
edly detected in eyes of patients undergoing vitrectomy
operations for PDR and diabetic macular edema [32–35].
The cellular eﬀects of VEGF are mediated primarily through
two closely related receptor tyrosine kinases VEGFR-1 (Flt1)
and VEGFR-2 (KDR/Flk1) [36]. Regulation of target genes
such as heptocyte growth factor (HGF), urinary and tissue
plasminogenactivator(uPA,tPA),matrixmetalloproteinase-
9 (MMP9) is then achieved through complex signaling path-
ways, including through protein kinase C (PKC) [37]. VEGF
inhibition has been shown to ameliorate retinal changes
including retinal neovascularization and breakdown of the
blood-retinal barrier [38–40]. A total of six polymorphisms
(rs25648, rs1570360, rs3095039, rs35569394, rs699947 and
rs2010963) in VEGF have been examined and of these, the
G allele of rs2010963 was signiﬁcantly associated with a
reduced risk of NPDR in patients with type 2 diabetes (OR =
0.62, 95% CI = 0.48–0.81, P = .0005) [31]. Considering that
VEGF has been implicated in neovascularization, it might
appear surprising that none of the polymorphisms so far
including rs2010963 has been signiﬁcantly associated with
PDR [31].
6. Angiotensin-IConverting Enzyme
(ACE,HumanChromosome 17q23)
Among the DR candidate genes, ACE is the most widely
studied. The well-known insertion deletion (I/D) polymor-
phism in ACE which results from the insertion/deletion
of a 287bpAlu sequence in intron 16 accounts for half
the variance of serum enzyme levels. Individuals who are
homozygous for the insertion allele (II genotype) have
signiﬁcantly lower levels of ACE compared to carriers of
the deletion allele (ID and DD genotypes) [41]. A meta-
analysis of six studies on this polymorphism in patients with
type 1 diabetes and seven studies in patients with type 2
diabetes suggested that there was no statistically signiﬁcant
association of this polymorphism and the development of
any form of diabetic retinopathy [31]. A second recent
independent meta-analysis corroborated this ﬁnding but
suggested that ACE I/D may be associated with PDR (OR =
1.37, 95% CI = 1.02–1.84) under a dominant genetic model
a s s u m i n ge i t h e rﬁ x e do rr a n d o me ﬀects [42].Journal of Ophthalmology 3
Table 1: Familial clustering of DR.
Type of Diabetes Patients/Study Evidence for familiar Clustering Reference
Type 1 DCCT subjects OR = 3.1, 95% CI = 1.2–7.8 [9]
Type 1 FinnDiane Study OR = 2.76, 95% CI = 1.25–6.11,
Heritability = 52%
[13]
Type 2 Asian Indians OR = 3.37, 95% CI = 1.56–7.29 [10]
Type 2 Mexican Americans OR = 1.72, 95% CI = 1.03–2.88 [11]
Type 2 Find-Eye Study Heritability = 27% [12]
7. Deﬁciency of CandidateGeneStudies
Apart from the few genes mentioned above, the overall
evidence for the remaining candidate genes investigated to
dateisweak[31].Severalfactorsarelikelyresponsibleforthis
situation, a primary one being small sample sizes. Some have
as little as 50 subjects while larger studies with more than
100 cases are decidedly uncommon [18, 29]. Meta-analyses
have been undertaken to present the overall evidence for an
association but this technique has well-known drawbacks,
including the possibility of publication bias which has to be
carefully assessed.
Another limitation is that most studies failed to take
into account the role of haplotype diversity at the candidate
gene locus. Studies so far have focused on single (and often
random) SNPs and, as such, cannot reasonably exclude a
gene as being important in DR since linkage disequilibrium
between these SNPs and the true functional SNP may be low
[20–23, 26]. To circumvent this problem, it will be poten-
tially useful to examine haplotype-disease associations. The
usefulness of this approach was demonstrated recently in the
case of ACE where risk haplotypes for diabetic nephropathy
(another important microvascular complication of diabetes)
were identiﬁed in independent studies [43, 44]. Another
point of note is that the reported studies have rarely taken
into account the potential inﬂuence of covariates. One such
covariate is diabetes duration, the importance of which has
been demonstrated through simulation studies [45]a sw e l l
as in epidemiological studies seeking to identify genes for
anothermicrovascularcomplicationofdiabetes(i.e.,diabetic
nephropathy) [46, 47].
8. LinkageStudies
Besides the candidate gene approach, whole genome linkage
studies have also been undertaken to identify chromosomal
regions which potentially harbor major genes for DR.
Three such studies have been reported and these have
been conducted on Mexican Americans and Pima Indians
with type 2 diabetes [48–50]( Table 2). With the possible
exception of human chromosome 1p36, the linkage evidence
for the other regions has not been replicated and this is
undoubtedly related to the very modest LOD scores initially
reported (Table 2).Geneticlinkageappearedtoexistforboth
advanced stages as well as earlier manifestations of DR [49].
The identities of the purported major susceptibility genes in
these linkage regions continue to remain elusive.
9. Genomewide Association Studies (GWASs)
Recent advances have made it possible to genotype the
h u m a ng e n o m ea tu pt oam i l l i o np o l y m o r p h i cs i t e si n
thousands of samples within a reasonable time frame. This
has heralded the era of genomewide association studies
(GWASs) which have been successful at pinpointing a
number of novel genes related to a spectrum of diseases
[51]. Unfortunately, no GWAS eﬀort to identify DR genes
has been reported to date. Extrapolating from the collective
GWAS experience [51, 52], one can nevertheless anticipate
that for any DR gene found through GWAS, the implicated
risk alleles will have limited eﬀect sizes with OR <1.4
while the risk allele frequencies will be quite frequent in
the population (>0.20). Thus, the risk alleles will be low
penetrant since many individuals will harbor the risk alleles,
but among these, the majority will tend to remain disease-
free. In addition, GWAS will not be expected to unmask
the identity of the major susceptibility genes for DR even
in regions that show linkage to this disease [52]. Finally,
the genes identiﬁed through GWAS will only account for a
very limited proportion of the familial clustering observed
for DR. Clinically, the genetic information gleaned from
GWAS will have limited utility as potential disease classiﬁers
[53].
However, balancing these modest expectations of GWAS
lies the prospect of identifying novel genes which can
undoubtedly shed fresh insight into the pathogenic path-
ways responsible for DR. Indeed, it is realistic to hope
that elucidation of these pathways can in the long
run lead to new molecular targets for pharmacological
intervention. Already, newer therapies based on known
pathogenic pathways particularly intravitreal antiangiogen-
esis agents that act to suppress VEGF are already being
evaluated, although the evidence base currently does not
yet support their routine use in the clinic [54]. In the
interim, good glycaemic and blood pressure control nec-
essarily remains the cornerstone in the prevention of DR
[54].
10. Conclusion
From the current survey of the human genetics of DR, it
is clear that this ﬁeld remains poorly developed. However,
therein lies the promise of impactful scientiﬁc discov-
eries if concerted and collaborative eﬀorts are mounted
to identify the genes responsible for DR. Just as the4 Journal of Ophthalmology
Table 2: Potential chromosomal regions linked to DR (LOD scores >1).
Chromosome Deﬁnition of DR Population LOD score Nearest genetic markers Reference
1p36 Retinopathy score in
worst eye Pima Indians 3.1 D1S3669 [50]
1p36 Any DR Mexican
Americans
1.24 GGAT2A07 [49]
2q37 Severe NPDR/PDR Mexican
Americans
1.11 AFM112yd4 [49]
3p26 Severe NPDR/PDR Mexican
Americans
1.29 GATA22G12 [49]
3q12 Severe NPDR/PDR Mexican
Americans
1.40 GATA68D03 [49]
3q12 Any DR Mexican
Americans
2.41 GATA68D03 [49]
3q26
Presence of at least
one microaneruysm,
hemorrahage or
proliferative DR
Pima Indians 1.36 D3S3053, D3S2427 [48]
7p15 Any DR Mexican
Americans
1.02 GATA41G07 [49]
9q21
Presence of at least
one microaneruysm,
hemorrhage or
proliferative DR
Pima Indians 1.46 D9S1120, D9S910 [48]
12p13 Any DR Mexican
Americans
2.47 GATA49D12 [49]
12q23 Severe NPDR/PDR Mexican
Americans
1.03 GATA85A04 [49]
15q25 Any DR Mexican
Americans
1.07 ATA28G05 [49]
15q26 Any DR Mexican
Americans
1.16 GATA22F01 [49]
International Human Genome and HapMap Projects have
propelled genetic discoveries in the past few years, the
added resources of the upcoming 1000 Genomes Project
(http://www.1000genomes.org/)a sw e l la sn e wg e n e t i ct e c h -
nologiesmaylikewiseprovebeneﬁcialtothisﬁeldofresearch
and lead to a rich harvest of insights into the biological
mechanisms underlying this debilitating complication.
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